BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

台灣神隆股份有限公司

 

Company Info

Name /ScinoPharm Taiwan

Address /No.1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan 74144, Taiwan

Website /www.scinopharm.com

Presenter

Name /Jannie Lin-林侑蓁

Title /Department of CDMO

Email /Jannie.Lin@scinopharm.com

Telephone /886-6-5052888 ext.2960

Fax /886-6-5052855

Mobile /

Company Type

Pharmaceutical

About the Company

Founded in 1997, ScinoPharm Taiwan is a global manufacturer of Active Pharmaceutical Ingredients (APIs), providing a wide array of APIs and the development and manufacturing services of intermediates. In addition to supplying famous pharmaceutical companies and generic drug manufacturers around the world, we also provide API outsourcing services for new drug development companies and patented big pharmaceutical companies.

Brief Description of main products or services

CRAM Services (CRO & CMO)
ScinoPharm offers world-class services in developing and manufacturing clinical, small-scale, and commercial-stage active pharmaceutical ingredients (APIs) and intermediates. Our dedicated contract research organization (CRO) and contract manufacturing organization (CMO) teams provide customers with fast, flexible, reliable, and competitive services.

Analytical Services
We offer “virtual companies” full-package consultation services, including the exploration of new synthetic molecules and their development and manufacturing. ScinoPharm provides the below analytical services:
Using advanced technologies to determine the purity of product, chemical structure analysis and identification of impurities, analysis of isomeric impurities, polymorphism study, particle size distribution, and hygroscopicity study. The analytical instruments include high-performance liquid chromatography, gas chromatography, mass spectroscopy, spectroscopy (NMR, DVS, XRPD, etc.), and other advanced instruments. In terms of contract development and manufacturing, the Company continues to demonstrate professional efficiency by fortifying hardware facilities and harnessing its soft power.

Injectable Production Capacity
Our injectable product line was approved by Taiwan Food Drug Administration (TFDA) for the first time in 2021. We submitted the U.S. Abbreviated New Drug Application (ANDA) for our peptide prefilled syringe, liquid injectables, and lyophilized injectable products, and hosted an on-site inspection conducted by the U.S. FDA in March 2022. Meanwhile, we launched our cartridge packaging and vial production lines as scheduled, taking a giant leap toward ScinoPharm's long-term strategic goal of becoming an all-inclusive pharmaceutical company

Contact Person

Name /Elsa Yang

Email /elsa.yang@scinopharm.com

Phone /886-6-505-2888 ext.2802